SYRACUSE, N.Y.--(

纽约州锡拉丘兹--(

BUSINESS WIRE

商业热线

)--Central New York Biotech Accelerator (CNYBAC). -– Zetagen Therapeutics, Inc., a private, clinical stage, biopharmaceutical company focused on developing proprietary carriers delivering tumoricidal therapies for metastatic and primary breast cancer, which may minimize patient side effects with the potential to increase survival rates, announced today in 2024 they nearly doubled their worldwide IP portfolio to 64 patents, spanning across 36 countries including the United States, Europe, Canada, Australia, Japan, United Kingdom, India, Sweden and Switzerland..

)--纽约中央生物技术加速器（CNYBAC）Zetagen Therapeutics，Inc.是一家私营的临床阶段生物制药公司，专注于开发专有载体，为转移性和原发性乳腺癌提供杀肿瘤治疗，这可能会最大程度地减少患者的副作用，并有可能提高生存率。他们于2024年宣布，他们的全球知识产权组合几乎翻了一番，达到64项专利，涵盖36个国家，包括美国、欧洲、加拿大、澳大利亚、日本、英国、印度、瑞典和瑞士。。

'It is heartening to witness this significant scientific research being acknowledged with these latest patent grants,'

“看到这项重要的科学研究得到这些最新专利授权的认可，令人鼓舞。”

said Joe C. Loy, member of the Executive Board and CEO of Zetagen Therapeutics.

Zetagen Therapeutics执行董事兼首席执行官乔·洛伊（JoeC.Loy）表示。

'Our ambition is to continue growing our intellectual property portfolio with discoveries around the development of Zeta-BC-003 and Zeta-BC-005 for the treatments of metastatic breast cancer, but also for future discoveries towards primary breast cancer treatments.'

“我们的目标是继续扩大我们的知识产权组合，围绕开发用于治疗转移性乳腺癌的Zeta-BC-003和Zeta-BC-005的发现，以及未来对原发性乳腺癌治疗的发现。”

Details of the latest patent awards for the company’s Life Science business are as follows:

公司生命科学业务的最新专利奖详情如下：

New molecular pathways, proprietary carriers, and optimum dose ranges to treat breast cancer.

治疗乳腺癌的新分子途径，专有载体和最佳剂量范围。

Zetagen has enlisted Foley & Lardner LLP as its intellectual property counsel and maintains a collaborative professional relationship with Steve Maebius, Esq. Foley & Lardner LLP is a prominent law firm with global reach and specialized expertise in Life Sciences intellectual property and strategic counsel..

Zetagen聘请Foley＆Lardner LLP担任其知识产权顾问，并与Steve Maebius，Esq保持合作专业关系。Foley＆Lardner LLP是一家知名的律师事务所，在生命科学知识产权和战略顾问方面具有全球影响力和专业知识。。

'The technologies patented by Zetagen in 2024 contain landmark science, which includes new chemicals and describes novel chemistries, and formulations of their proprietary drug-carrier platform, specific to locoregional delivery of these new chemical entities, improving breast cancer treatments,'

“Zetagen于2024年获得专利的技术包含里程碑式的科学，其中包括新的化学物质，并描述了新的化学物质及其专有药物载体平台的配方，专门用于这些新化学物质的局部区域输送，从而改善乳腺癌的治疗方法。”

said Bryan S. Margulies, MS, PhD, CSO, Zetagen Therapeutics, Inc.

Zetagen Therapeutics，Inc.CSO博士、MS Bryan S.Margulies说。

About Zetagen Therapeutics

关于Zetagen Therapeutics

Founded in 2015, Zetagen Therapeutics is a private, clinical-stage, biopharmaceutical company dedicated to developing proprietary carriers delivering tumoricidal therapies for metastatic and primary breast cancer, minimizing patient side effects with the potential to increase survival rates.

Zetagen Therapeutics成立于2015年，是一家私营的临床阶段生物制药公司，致力于开发专有载体，为转移性和原发性乳腺癌提供杀肿瘤治疗，最大限度地减少患者的副作用，提高生存率。

The US Food & Drug Administration (FDA) has recognized Zetagen’s discoveries with multiple Breakthrough Designations including ZetaMet™ (Zeta-BC-003).

美国食品和药物管理局（FDA）已经认可了Zetagen的发现，包括ZetaMet™（Zeta-BC-003）在内的多个突破性名称。

Zetagen with FDA approval via the Expanded Access (Compassionate Use) program has treated 7x patients with ZetaMet™ (Zeta-BC-003) with published results in multiple peer-reviewed journals. Zetagen is presently enrolling a ZetaMet™ (Zeta-BC-003) Phase IIa clinical trial for treatment of metastatic breast cancer in the spine at the University of British Columbia, Vancouver, BC..

Zetagen通过扩展访问（同情使用）计划获得FDA批准，已治疗了7倍ZetaMet™（Zeta-BC-003）患者，并在多个同行评审期刊上发表了结果。Zetagen目前正在不列颠哥伦比亚大学温哥华分校注册ZetaMet™（Zeta-BC-003）IIa期临床试验，用于治疗脊柱转移性乳腺癌。。

The company's ‘Zeta” platform encompasses the following oncological drug candidates ZetaMet™ (Zeta-BC-003), ZetaMet-P™ (Zeta-PC-004) and ZetaMAST™ (Zeta-MBC-005). To learn more, visit

该公司的“Zeta”平台包括以下肿瘤候选药物ZetaMet™（Zeta-BC-003），ZetaMet-P™（Zeta-PC-004）和ZetaMAST™（Zeta-MBC-005）。要了解更多信息，请访问

www.zetagen.com

www.zetagen.com

.

.

Zetagen Upcoming Events

Zetagen即将举行的活动

Zetagen is attending the JP Morgan Healthcare Conference.

泽塔根正在参加摩根大通医疗保健会议。

Forward-Looking Statements

前瞻性声明

This press release contains certain forward-looking statements with the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature.

本新闻稿包含1933年《证券法》第27A节、1934年《证券交易法》第21E节和经修订的《私人证券诉讼改革法》所指的某些前瞻性声明，包括与公司产品开发、临床和监管时间表、市场机会、竞争地位、可能或假定的未来经营成果、业务战略、潜在增长机会和其他具有预测性质的声明有关的前瞻性声明。

These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions..

这些前瞻性陈述基于对我们经营的行业和市场的当前预期、估计、预测和预测以及管理层当前的信念和假设。。

Source:

资料来源：

Zetagen Therapeutics, Inc.

Zetagen Therapeutics公司。